Navigating the Evolving Landscape of Precision Medicine in Gastrointestinal Cancers

T-DM1 was tolerable in HER2-positive biliary tract adenocarcinoma but did not significantly improve progression-free survival.

In this episode of Emerging Experts, Michael LaPelusa, MD, shares his insights, experiences, and passion for cancer research, particularly in the realm of gastrointestinal cancers.

NALRIFOX showed numerically better overall survival vs FOLFIRINOX as frontline treatment in PDAC, per real-world analysis results.

In season 4, episode 1 of Targeted Talks, Benjamin L. Schlechter, MD, discuses new studies in the gastrointestinal cancers space.

Adding CRT to chemotherapy did not improve RFS in resected gallbladder cancer in the phase 3 ACCELERATE trial.

The combination of pelareorep and modified FOLFIRINOX with or without atezolizumab had an acceptable safety in newly diagnosed metastatic pancreatic ductal adenocarcinoma.